- Home
- GOOD vs TYRA Comparison
GOOD vs TYRA Comparison
Compare GOOD & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOOD
- TYRA
- Stock Information
- Founded
- GOOD 2003
- TYRA 2018
- Country
- GOOD United States
- TYRA United States
- Employees
- GOOD N/A
- TYRA 38
- Industry
- GOOD Real Estate Investment Trusts
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- GOOD Real Estate
- TYRA Health Care
- Exchange
- GOOD Nasdaq
- TYRA Nasdaq
- Market Cap
- GOOD 775.6M
- TYRA 666.4M
- IPO Year
- GOOD N/A
- TYRA 2021
- Fundamental
- Price
- GOOD $15.72
- TYRA $13.17
- Analyst Decision
- GOOD Buy
- TYRA Strong Buy
- Analyst Count
- GOOD 2
- TYRA 6
- Target Price
- GOOD $15.25
- TYRA $30.50
- AVG Volume (30 Days)
- GOOD 211.6K
- TYRA 247.2K
- Earning Date
- GOOD 02-18-2025
- TYRA 03-18-2025
- Dividend Yield
- GOOD 7.67%
- TYRA N/A
- EPS Growth
- GOOD N/A
- TYRA N/A
- EPS
- GOOD 0.27
- TYRA N/A
- Revenue
- GOOD $149,388,000.00
- TYRA N/A
- Revenue This Year
- GOOD N/A
- TYRA N/A
- Revenue Next Year
- GOOD $1.84
- TYRA N/A
- P/E Ratio
- GOOD $59.25
- TYRA N/A
- Revenue Growth
- GOOD 1.22
- TYRA N/A
- 52 Week Low
- GOOD $11.89
- TYRA $11.89
- 52 Week High
- GOOD $17.88
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- GOOD 37.31
- TYRA 43.64
- Support Level
- GOOD $15.64
- TYRA $12.27
- Resistance Level
- GOOD $16.11
- TYRA $13.79
- Average True Range (ATR)
- GOOD 0.26
- TYRA 0.71
- MACD
- GOOD -0.04
- TYRA 0.03
- Stochastic Oscillator
- GOOD 20.25
- TYRA 51.09
About GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).